Management of rifampicin-resistant tuberculosis in conflict-affected areas: the case of Iraq

HM Tesfahun, L Al-Salihi, NA Al-Ani, AA Mankhi, A Mohammed, CAE Lim, RA Al-Hilfi, CG Jouego, T Decroo, K Moussally, G Ferlazzo, P Isaakidis

Research output: Contribution to journalA1: Web of Science-articlepeer-review

Abstract

Since December 2019, the World Health Organization (WHO) has encouraged National Tuberculosis Programs to deprioritize the use of injectable-containing regimens and roll-out all-oral bedaquiline-containing regimens for rifampicin-resistant tuberculosis (RR-TB) treatment. Consequently, Iraq gradually replaced the injectable-containing regimen with an all-oral regimen, including bedaquiline. To assess treatment enrolment and outcomes of both regimens during a transitioning phase in Iraq, where health system services are recovering from decades of war, we conducted a nationwide retrospective cohort study using routinely collected programmatic data for patients enrolled between 2019–2021. We describe treatment enrolment and use logistic regression to identify predictors of unfavorable treatment outcomes (failure, death, or lost to follow-up), including regimen type. Nationwide, a total of 301 RR-TB patients started treatment, of whom 167 concluded treatment. The proportion of patients enrolled on the all-oral regimen increased from 53.2% (50/94) in 2020, to 75.5% (80/106) in 2021. Successful treatment was achieved in 82.1% (32/39) and 63.3% (81/128), for all-oral and injectable-containing regimens respectively. Moreover, the proportion of lost to follow-up was lower among those treated with the all-oral versus the long injectable-containing regimen; respectively 2.6% (1/39) versus 17.9% (23/128: p = 0.02). Unfavorable treatment outcome was associated with male gender (aOR 2.12, 95%CI:1.02–4.43) and age <15 years (vs 30–49 years, aOR 5.80, 95%CI:1.30–25.86). Regimen type (aOR 2.37, 95%CI: 0.91–6.13) was not significantly associated with having an unfavorable treatment outcome. In Iraq, the use of bedaquiline-containing all-oral regimen resulted in a high treatment success and reduced lost to follow-up.
Original languageEnglish
Article numbere0296952
JournalPLoS ONE
Volume19
Issue number1
Number of pages14
ISSN1932-6203
DOIs
Publication statusPublished - 2024

Fingerprint

Dive into the research topics of 'Management of rifampicin-resistant tuberculosis in conflict-affected areas: the case of Iraq'. Together they form a unique fingerprint.

Cite this